Specify a stock or a cryptocurrency in the search bar to get a summary
Prescient Therapeutics Ltd
PTXPrescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block an cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia. Address: 100 Albert Road, Melbourne, VIC, Australia, 3205
Analytics
WallStreet Target Price
0.21 AUDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PTX
Dividend Analytics PTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PTX
Stock Valuation PTX
Financials PTX
Results | 2019 | Dynamics |